In this article
What to know
- ONTRAC studied nicotinamide, not NR or NMN.
- The transplant-recipient trial did not reproduce the favorable clinical result.
- The population and cancer endpoint must stay beside the relative effect.
A specific vitamin is not the whole category
A favorable skin-cancer trial of nicotinamide does not establish that NR, NMN or an NAD injection prevents skin cancer. The names share biological relationships, but the interventions are not interchangeable. ONTRAC randomized 386 people with at least two prior nonmelanoma skin cancers in five years to nicotinamide 500 mg twice daily or placebo for 12 months. It reported a 23% lower rate of new nonmelanoma skin cancers during treatment. [1] That is a specific result, not a category-wide endorsement of products marketed around NAD.
The buying consequence is simple: identify the exact molecule before deciding whether the cited experiment is about the product being sold.
The outcome is a rate in a high-risk group
The ONTRAC result concerns the rate of new basal-cell and squamous-cell cancers in an enrolled high-risk population. It should not be restated as a 23-percentage-point reduction in every person's risk, a melanoma-prevention result or a promise for people without that history. The paper's separate endpoints also should not be blended into one universal claim. [1]
Relative effects can sound larger than the practical decision they describe. A useful clinical explanation places the starting risk, measured outcome and uncertainty beside the relative figure. That makes the result more informative, not less impressive. Removing the population and endpoint turns a bounded experiment into a slogan that the trial cannot support.
The transplant trial is an important contrast
ONTRANS tested nicotinamide in immunosuppressed organ-transplant recipients with a history of keratinocyte cancers. It enrolled 158 participants, stopped early because of recruitment difficulty and did not show fewer new keratinocyte cancers over 12 months. [2] This is not a trivial footnote to the earlier positive result. It shows why a different clinical population needs its own experiment even when the molecule and nominal regimen appear similar.
The study was smaller than planned, so precision and power deserve attention. A null result is still a result. It should not be retold as a positive finding simply because an earlier trial in another population was encouraging.
To understand the related evidence, read Nr versus nmn human trials.
Related precursors need their own evidence
The NR obesity trial is an example of a different NAD-related intervention with a different physiological question. [3] It cannot independently confirm a nicotinamide skin-cancer effect. Conversely, the skin-cancer papers cannot validate NR's metabolic claims. A shared pathway makes the relationship scientifically interesting, but it is not a license to transfer outcomes between products.
This is especially relevant to a retail page that lists several vitamin B3 terms together. A long reference list may contain sound research while failing to test the ingredient actually in the bottle. Read the intervention column before the result column. The extra minute prevents a meaningful study from becoming support for an unrelated purchase.
Prevention studies do not replace care
The papers studied an intervention alongside clinical follow-up in defined risk settings. [1] [2] They do not establish that a supplement can replace dermatological evaluation or other measures appropriate to an individual's history. Nor do they diagnose risk from an online questionnaire. Someone with previous skin cancers has a more useful question for the treating clinician than which NAD-branded product looks most advanced.
A care discussion should specify the intended outcome and the person's circumstances before selecting a product. It should also explain why an exact preparation is being considered, what other measures remain relevant and how the plan will be reviewed. An attractive mechanism cannot substitute for that individualized reasoning.
What the labels should let you distinguish
Nicotinamide is also called niacinamide. NR is nicotinamide riboside, and NMN is nicotinamide mononucleotide. The added words identify different compounds, not marketing versions of the same tested pill. When comparing labels, write out the active name rather than relying on the large NAD letters on the front.
If a formulation contains several components, list each one separately. Evidence for one ingredient does not demonstrate the mixture, its dose or its delivery system. This is a general rule for reading the clinical comparison, not a recommendation to assemble a supplement stack. A clear label helps determine whether evidence is relevant; it cannot establish the desired result by itself.
For the practical product comparison, see Compare simple NR and a blend.
The conclusion a consumer can use
ONTRAC is evidence for a specific nicotinamide strategy in a defined high-risk population. ONTRANS limits confidence in extending that story to transplant recipients. Neither establishes skin-cancer prevention from an NR capsule, NMN supplement or injectable NAD service. [1] [2] A responsible product comparison should keep that boundary visible even when the biological rationale is appealing.
The useful next step is a conversation grounded in personal skin-cancer history and the actual studied compound. For a general NAD shopper, this is a lesson in reading references: related chemistry does not create clinical equivalence. A precise molecule and a precise population carry more decision value than a product page that treats every vitamin B3 paper as support for every longevity claim.
Sources
Research describes groups and specific study conditions. Your medical history, symptoms and treatment decisions require advice from your own qualified clinician.
